Rituximab ‘impairs COVID-19 vaccine efficacy’
Two studies may help guide timing of both treatment and inoculation, rheumatologists say
Time since rituximab infusion and levels of B-cell reconstitution may be crucial to a humoral response to the mRNA COVID-19 vaccines, two separate small studies suggest.
A study of 89 patients from a rheumatology practice in New York City has shown that among several biological DMARDS and other therapies, only rituximab was associated with a significant risk of the patient having no serological response postvaccination.
